Asset Details
Do you wish to reserve the book?
Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens
Do you wish to request the book?
Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens
2017
Overview
•SAM vaccines were engineered to express prototype bacterial antigens from GAS and GBS.•Mice immunized with both vaccines produced fully functional serum antibodies.•Antibodies elicited by SAM vaccines conferred protection in mouse infection models.•SAM vaccines have the potential to be used for a broad range of targets.
Nucleic acid vaccines represent an attractive approach to vaccination, combining the positive attributes of both viral vectors and live-attenuated vaccines, without the inherent limitations of each technology. We have developed a novel technology, the Self-Amplifying mRNA (SAM) platform, which is based on the synthesis of self-amplifying mRNA formulated and delivered as a vaccine. SAM vaccines have been shown to stimulate robust innate and adaptive immune responses in small animals and non-human primates against a variety of viral antigens, thus representing a safe and versatile tool against viral infections. To assess whether the SAM technology could be used for a broader range of targets, we investigated the immunogenicity and efficacy of SAM vaccines expressing antigens from Group A (GAS) and Group B (GBS) Streptococci, as models of bacterial pathogens. Two prototype bacterial antigens (the double-mutated GAS Streptolysin-O (SLOdm) and the GBS pilus 2a backbone protein (BP-2a)) were successfully expressed by SAM vectors. Mice immunized with both vaccines produced significant amounts of fully functional serum antibodies. The antibody responses generated by SAM vaccines were capable of conferring consistent protection in murine models of GAS and GBS infections. Inclusion of a eukaryotic secretion signal or boosting with the recombinant protein resulted in higher specific-antibody levels and protection. Our results support the concept of using SAM vaccines as potential solution for a wide range of both viral and bacterial pathogens, due to the versatility of the manufacturing processes and the broad spectrum of elicited protective immune response.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Animals
/ Antibodies, Bacterial - blood
/ Antigens
/ Antigens, Bacterial - biosynthesis
/ Antigens, Bacterial - genetics
/ Antigens, Bacterial - immunology
/ DNA
/ Female
/ fimbriae
/ GAS
/ Genes
/ Genomes
/ Mice
/ Primates
/ Proteins
/ RNA, Messenger - biosynthesis
/ SAM GBS
/ Streptococcal Infections - prevention & control
/ Streptococcal Vaccines - administration & dosage
/ Streptococcal Vaccines - genetics
/ Streptococcal Vaccines - immunology
/ Streptococcus agalactiae - genetics
/ Streptococcus agalactiae - immunology
/ Streptococcus pyogenes - genetics
/ Streptococcus pyogenes - immunology
/ Vaccine
/ Vaccines
